The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subsets of interferon signaling and response to immune checkpoint blockade.
 
Daniel Lee
No Relationships to Disclose
 
Brooke Horowitch
No Relationships to Disclose
 
Min Ding
No Relationships to Disclose
 
Sandra Martinez-Morilla
Employment - Boehringer Ingelheim
 
Thazin Nwe Aung
No Relationships to Disclose
 
Feriel Ouerghi
No Relationships to Disclose
 
Xueting Wang
No Relationships to Disclose
 
Wei Wei
Employment - Takeda
 
William Damsky
No Relationships to Disclose
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Repertoire Immune Medicines; Rootpath
Consulting or Advisory Role - Adagene; Adaptimmune; Agenus; Alligator Bioscience; AnaptysBio; AstraZeneca/MedImmune; Biond Biologics; BioNTech; Bristol-Myers Squibb; Dragonfly Therapeutics; Genocea Biosciences; Gilead Sciences; immunocore; Innate Pharma; Iovance Biotherapeutics; ITeos Therapeutics; Jazz Pharmaceuticals; Kadmon; Kanaph Therapeutics; Merck; Molecular Partners; Numab; Ocellaris Pharma; OncoSec; Pfizer; Pierre Fabre; PIOtx; Pliant; Regeneron; Sapience Therapeutics; Seagen; Simcha Therapeutics; Simcha Therapeutics; ST Cube; Targovax; Tessa Therapeutics; Turnstone Bio; Verastem; Xilio Therapeutics
Other Relationship - CEC Oncology; Physicans' Education Resource
 
Harriet M. Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Celldex; ChemoCentryx; Clinigen Group; GI Reviewers; Gigagen; Iovance Biotherapeutics; Merck; Pliant; Pliant; Seranova Bio; Seranova Bio; Shionogi; Signatera
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
David L. Rimm
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Cell Signaling Technology; Cepheid; Daiichi Sankyo; Danaher; GlaxoSmithKline; Konica Minolta; Merck; NanoString Technologies; NextCure; PAIGE.AI; Regeneron; Roche; Sanofi; Verily
Research Funding - Amgen (Inst); Cepheid (Inst); Konica Minolta (Inst); Navigate Biopharma (Inst); NextCure (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Expert Testimony - Bryan Cave Leighton Paisner
 
Jeffrey Joseph Ishizuka
Stock and Other Ownership Interests - Jounce Therapeutics; Kronos Bio
Consulting or Advisory Role - Danger Bio; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".